Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTAF: Botulinum Toxin for Prevention of Post-operative Atrial Fibrillation
NCT04075981Phase 3Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2019
- Primary completion
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in Atrial fibrillation (AFib), sponsored by Assistance publique - Hôpitaux de Paris. Started Sep 2019; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04075981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075981.